ClinicalTrials.gg
Active, not recruitingNCT07074665Updated Aug 24, 2026

Dose Finding Trial of R21/Matrix-M in School Children

A Phase 2 interventional study of 5µg R21/50µg Matrix-M and 10µg R21/50µg Matrix-M in Malaria (Plasmodium Falciparum), sponsored by University of Oxford. Active, not recruiting at 1 site in Burkina Faso. Open to participants aged 6 Years to 8 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by University of Oxford · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
6 Years to 8 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Malaria, Falciparum by University of Oxford — 3 open to participants now, 9 under way, 1 of them phase 3. Malaria, Falciparum · University of Oxford.

Planned enrollment
33rd of 47
40 · median 62
Started
2026
with 1 other
Phase 2
5 of 54
none open now
Registered
52nd of 54
by date

Among the 54 studies in Malaria, Falciparum by University of Oxford, this one is the 33rd largest by planned enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 2, and was the 52nd registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

3 of the 54 studies in Malaria, Falciparum by University of Oxford are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 8 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Malaria, Falciparum by University of Oxford, or all of them as a file.
02

Study summary

This trial is a double-blind, randomised, trial recruiting participants from the R21 phase IIb trial (VAC 076) which took place between May 2019 and July 2023 in Nanoro, Burkina Faso.

Participants (n=30-40) who have previously received four doses of the 5µg R21/50µg Matrix-M malaria vaccine in VAC 076 will be randomised to receive either 5µg R21/50µg Matrix-M or 10µg R21/50µg Matrix-M. Safety and immunogenicity of a booster at school age at these two different doses will be assessed. Participants will be followed up for one year after the booster.

This trial is co-funded by the Serum Institute of India and Coefficient Giving.

03

Conditions studied

  • Malaria (Plasmodium Falciparum)

Browse trials for

Keywords

  • Malaria Vaccine
  • R21/Matrix-M
04

Who can participate

Ages eligible
6 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The child received four doses of R21/Matrix-M in the phase IIb study evaluating R21/MatrixM in Nanoro, Burkina Faso (VAC 076).
  • Signed /thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child to join the trial.
  • The investigator believes that the parents/guardians can and will comply with the requirements of the protocol if the child is enrolled in the study.
  • The child is a permanent resident of the study area and is expected to remain a resident for the duration of the trial.

Exclusion criteria

Exclusion Criteria:

  • The child is enrolled in another malaria vaccine trial.
  • The child has a history of allergic disease or reactions likely to be exacerbated by any component of the malaria vaccine.
  • The child has a history of allergic reactions, significant IgE-mediated events or anaphylaxis to previous immunisations.
  • The child has major congenital defects.
  • The child has anaemia associated with clinical signs of symptoms of decompensation, or a of ≤ 5.0 g/dL.
  • The child has been administered immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
  • The child has malnutrition requiring hospital admission.
  • The child has an acute or chronic, pulmonary, cardiovascular, gastrointestinal, endocrine, neurological, skin, hepatic or renal functional abnormality, as determined by medical history, physical examination or laboratory tests.
  • Children currently meeting the WHO criteria for disease of stage 3 or 4 severity. A previous history of stage 3 or 4 disease is not an exclusion. Note: There will be no routine testing for HIV. Positive diagnoses will be recorded at screening if known.
  • The child has received an drug or investigational vaccine other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • The child is currently participating in another clinical trial if likely to affect data interpretation of this trial.
  • The child has any significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Group A

    Participants in this arm will be given one dose of 5µg R21/50µg Matrix-M

    Biological: 5µg R21/50µg Matrix-M

  • Experimental
    Group B

    Participants in this arm will be given one dose of 10µg R21/50µg Matrix-M

    Biological: 10µg R21/50µg Matrix-M

Interventions

  • Biological5µg R21/50µg Matrix-M

    R21/Matrix-M is a vaccine against P. falciparum malaria, which has WHO prequalification and policy recommendation in children over 5 months old in malaria endemic areas. The standard paediatric dose is 5µg R21/50µg Matrix-M.

  • Biological10µg R21/50µg Matrix-M

    R21/Matrix-M is a vaccine against P. falciparum malaria, which has WHO prequalification and policy recommendation in children over 5 months old in malaria endemic areas. 10µg R21/50µg Matrix-M is the standard adult dose.

06

What researchers measure

Primary outcomes

  1. Reactogenicity

    Reactogenicity of an additional late booster of R21/Matrix-M at different doses, in school age children living in Burkina Faso. This will be measured through: 1) the occurrence of solicited local reactogenicity signs and symptoms for 7 days following the vaccination and 2) the occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination.

    Time frame: 7 days after vaccination

  2. Safety - unsolicited AEs

    Safety of an additional late booster of R21/Matrix-M at different doses, in school age children living in Burkina Faso will be assessed through the occurrence of unsolicited adverse events for 28 days following the vaccination.

    Time frame: 28 days following vaccination

Secondary outcomes

  1. Immunogenicity

    Humoral immunogenicity by anti-CSP antibody concentrations after school age booster of R21/Matrix-M at different doses.

    Time frame: At baseline and one, six and twelve months after vaccination

  2. Safety - SAEs

    Serious adverse events (SAEs) following school age booster vaccination.

    Time frame: 1 year after vaccination

  3. Safety - deaths

    Any deaths following school age booster vaccination

    Time frame: 1 year after vaccination

07

Study locations

1 site
  • Unité de Recherche Clinique de Nanoro (URCN)
    Nanoro, PO Box 11 BP 218 Ouaga CMS 11, Burkina Faso
08

References and documents

Individual participant data

Plan to share: Yes — Yes de-identified individual participant data collected in this study may be made available to other researchers outside the main trial team. This could include data on vaccinations, health, demographics or immunology results. Any proposals for using the study data will be reviewed and approved by the sponsor trial team.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2027, 13 months after the start.

Of 39 phase 2 interventional studies under Malaria, Falciparum, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's planned 13 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jul 20, 2025
StartActual
Feb 18, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07074665
Collaborators
Institut de Recherche en Sciences de la Sante, Burkina Faso
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Feb 18, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Aug 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion